Therapeutic R&D

SITE MAP


Ixchel develops novel known chemical compounds and generates IP protection including: novel indication (use) patents, orphan designation status, dosing patents, and formulation patents including mixtures of active compounds.

Friedreich’s ataxia (FA) is a serious, crippling neurodegenerative and cardiodegenerative disease that leads to early death. This mitochondrial-inherited disease is considered orphan; however, it is also the most prevalent recessive ataxia, affecting 6,000 individuals in North America and 15,000 in Europe. There is no approved therapy for FA in the US or EU, hence there is a great unmet need.

CONTACT US

New Chemical Entities

FRIEDREICH'S ATAXIA - IXC 109

© 2017 Ixchel Pharma

Gino Cortopassi

(530) 304-6810

​gino@ixchelpharma.com

​gacortopassi@gmail.com